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IMPORTANCE Cancer is among the leading causes of death worldwide. Current estimates of
cancer burden in individual countries and regions are necessary to inform local cancer
control strategies.
OBJECTIVE To estimate mortality, incidence, years lived with disability (YLDs), years of life
lost (YLLs), and disability-adjusted life-years (DALYs) for 28 cancers in 188 countries by sex
from 1990 to 2013.
EVIDENCE REVIEW The general methodology of the Global Burden of Disease (GBD) 2013
study was used. Cancer registries were the source for cancer incidence data as well as
mortality incidence (MI) ratios. Sources for cause of death data include vital registration
system data, verbal autopsy studies, and other sources. TheMI ratios were used to transform
incidence data to mortality estimates and cause of death estimates to incidence estimates.
Cancer prevalence was estimated using MI ratios as surrogates for survival data; YLDs were
calculated bymultiplying prevalence estimates with disability weights, which were derived
from population-based surveys; YLLs were computed bymultiplying the number of
estimated cancer deaths at each age with a reference life expectancy; and DALYs were
calculated as the sum of YLDs and YLLs.
FINDINGS In 2013 there were 14.9million incident cancer cases, 8.2 million deaths, and
196.3 million DALYs. Prostate cancer was the leading cause for cancer incidence (1.4 million)
for men and breast cancer for women (1.8 million). Tracheal, bronchus, and lung (TBL) cancer
was the leading cause for cancer death in men and women, with 1.6 million deaths. For men,
TBL cancer was the leading cause of DALYs (24.9million). For women, breast cancer was the
leading cause of DALYs (13.1 million). Age-standardized incidence rates (ASIRs) per 100 000
and age-standardized death rates (ASDRs) per 100 000 for both sexes in 2013 were higher in
developing vs developed countries for stomach cancer (ASIR, 17 vs 14; ASDR, 15 vs 11), liver
cancer (ASIR, 15 vs 7; ASDR, 16 vs 7), esophageal cancer (ASIR, 9 vs 4; ASDR, 9 vs 4), cervical
cancer (ASIR, 8 vs 5; ASDR, 4 vs 2), lip and oral cavity cancer (ASIR, 7 vs 6; ASDR, 2 vs 2), and
nasopharyngeal cancer (ASIR, 1.5 vs 0.4; ASDR, 1.2 vs 0.3). Between 1990 and 2013, ASIRs for
all cancers combined (except nonmelanoma skin cancer and Kaposi sarcoma) increased by
more than 10% in 113 countries and decreased bymore than 10% in 12 of 188 countries.
CONCLUSIONS AND RELEVANCE Cancer poses amajor threat to public health worldwide, and
incidence rates have increased in most countries since 1990. The trend is a particular threat
to developing nations with health systems that are ill-equipped to deal with complex and
expensive cancer treatments. The annual update on the Global Burden of Cancer will provide
all stakeholders with timely estimates to guide policy efforts in cancer prevention, screening,
treatment, and palliation.
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C ancer caused over 8million deathsworldwide in 2013 andhas moved from the third leading cause of death in 1990to the second leading cause behind cardiovascular dis-
ease in 2013.1-3 Substantial progress has beenmade in recent years
with regard to prevention and treatment options for certain
cancers.4-6 However, despite this progress, cancer burden is in-
creasing owing to a growing and aging global population as well as
risk factors like smoking, obesity, anddietarypatterns. Toappropri-
ately allocate resources to prevention, screening, diagnosis, treat-
ment, andpalliativecareand tomonitor their effectiveness, it isnec-
essary tohave timely informationaboutcancerburden for individual
countries.TheGlobalBurdenofDisease(GBD)studyprovidesacom-
prehensive assessment of incidence,mortality, anddisability for all
major diseases and injuries. Herein, we present detailed results of
the GBD 2013 study1 for 28 cancer groups covering cancer inci-
dence,mortality, anddisability for 188countries from1990 to2013
for both sexes and different age groups.
A Video summary of this article is available on the JAMA
Oncologywebsite.
Methods
ThegeneralmethodsthathavebeenusedintheGBDstudyhavebeen
publishedpreviously.1,2,7-14Thepresentstudyspecificallyexplains the
methodological componentspertainingtocancerestimationforGBD
2013. Box 1 includes a list of the figures and tables in this article.
Further details aboutmethods and data sources are provided in the
eAppendix, eFigures, andeTables in theSupplement, andBox2con-
tains a list of the supplementary figures and tables. Additional infor-
mation is available fromtheauthors inweb tables 1 through9,which
areavailableatthewebaddresses listedinBox3.Hereinafter,citations
toweb tables are for those given inBox 3.
The analytical strategy can be broken into 7 components, as
shown in eFigure 1 in the Supplement. The first step involved ex-
traction of mortality and incidence data from data sources col-
lected for theGBDstudy.Dataoncancer incidenceandcancermor-
talityweresoughtfromindividualcancerregistries, literaturereviews,
and the Cancer Incidence in Five Continents (CI5) series.15-24 Only
data representative of the registries’ catchment area and including
all cancer sites forboth sexeswereused.Themost recentdataavail-
able for any source until 2012 were incorporated. eTable 1 in the
Supplement lists cancer registrydatausedbycountry. Justoverhalf
(53%) of cancer incidence datawere reported in CI5,whereas 47%
came from cancer registries from other sources. Data were ex-
tracted at the most detailed cause- and age-specific level. Interna-
tional Classification of Diseases, Ninth Revision (ICD-9) and Interna-
tional Classification of Diseases, Tenth Revision (ICD-10) codes for
each GBD cancer group as well as steps explaining data prepara-
tion can be found in the eAppendix in the Supplement. Twenty-
eight cancer groupsweredefined that includeall ICD codespertain-
ing to neoplasms (ICD-9, 140-239; ICD-10, C00-D49) except for
Kaposi sarcoma (KS) (C46) and nonmelanoma skin cancer (NMSC)
(C44). eTable 3 in the Supplement lists the ICD-9 and ICD-10 codes
included in each cancer group.
In thesecondstep,mortality incidence(MI) ratios (cancerdeaths
divided by cancer incident cases) were estimated for each cancer
site, country, age, sex, and year.
At a Glance
• In 2013, there were 14.9million new cancer cases and 8.2 million
cancer deaths.
• For women, breast cancer was the leading cause of
disability-adjusted life-years (DALYs) globally and in developed
and developing countries.
• For men, lung cancer was the leading cause of DALYs globally and
in developed and developing countries.
• Formen, incident caseshave increased themost for prostate cancer
at theglobal setting and indevelopedanddeveloping countries.
• For women at the global level, incident cases have increased the
most for non-Hodgkin lymphoma; in developed countries,
incident cases have increased themost for kidney cancer; in
developing countries, incident cases have increased themost for
breast cancer.
Box 1. List of Figures and Tables in the Article
Figure 1. Age-Specific Global Contributions of Cancer Types to
Total Cancer Incidence andMortality, 2013
Figure 2. Relative Changes in Age-Standardized Incidence and
Death Rates in Both Sexes for All Cancers Except NMSC and KS in
188 Countries From 1990 to 2013
Figure 3. Cancers Ranked by Numbers of Incident Cases in Both
Sexes, Globally, by Development Status, and in the 50Most
Populous Countries, 2013
Figure 4. Cancers Ranked by Numbers of Deaths in Both Sexes,
Globally, by Development Status, and in the 50Most Populous
Countries, 2013
Figure 5. Cancers Ranked Globally and for Both Sexes by
Absolute Years of Life Lost (YLLs) Including the Percentage
Change in Absolute YLLs and the Percentage Change in the
Age-Standardized YLL Rate Between 1990 and 2013
Figure 6. Trends in Age-Standardized Incidence Rates for Tracheal,
Bronchus, and Lung Cancer, 1990-2013
Figure 7. Trends in Age-Standardized Incidence Rates for Female
Breast Cancer, 1990-2013
Figure 8. Trends in Age-Standardized Incidence Rates for Colon
and Rectum Cancer, 1990-2013
Figure 9. Trends in Age-Standardized Incidence Rates for Prostate
Cancer, 1990-2013
Figure 10. Trends in Age-Standardized Incidence Rates for
Stomach Cancer, 1990-2013
Figure 11. Trends in Age-Standardized Incidence Rates for Liver
Cancer, 1990-2013
Figure 12. Trends in Age-Standardized Incidence Rates for Cervical
Cancer, 1990-2013
Figure 13. Trends in Age-Standardized Incidence Rates for
Non-Hodgkin Lymphoma, 1990-2013
Figure 14. Trends In Age-Standardized Incidence Rates for
Esophageal Cancer, 1990-2013
Figure 15. Trends in Age-Standardized Incidence Rates for
Leukemia, 1990-2013
Table 1. Incidence and Deaths for All Cancers and 28 Cancer
Groups
Table 2. Decomposition Analysis of Cancer Trends in Global
Incidence, Both Sexes, 1990 to 2013
Clinical Review& Education Special Communication The Global Burden of Cancer 2013
506 JAMAOncology July 2015 Volume 1, Number 4 (Reprinted) jamaoncology.com
Downloaded From: https://jamanetwork.com/ by a Iran University of Medical Sciences User  on 12/07/2019
Copyright 2015 American Medical Association. All rights reserved.
Box 2. List of Supplementary Figures and Tables
eFigure 1. Flowchart for GBD cancer estimation process
eFigure 2. Percent increase in mortality by GBD cancer category
after redistribution of different categories of garbage code
(2008, only countries using ICD-10)
eFigure 3. Flowchart of algorithm used to adjust MI ratios
eFigure 4a. Cancer ranking by total incidence based on global level
for developing and developed regions and all countries, both sexes,
2013
eFigure 4b. Cancer ranking by total deaths basedonglobal level for
developing anddeveloped regions and all countries, both sexes, 2013
eFigure 5a. Proportion of deaths due to underlying causes, global,
both sexes, all ages, 2013. Non-communicable causes are shown in
blue, communicable, maternal, neonatal and nutritional causes are
shown in red, and injury causes are shown in green
eFigure 5b. Proportion of deaths due to underlying causes, global,
both sexes, all ages, 1990. Non-communicable causes are shown in
blue, communicable, maternal, neonatal and nutritional causes are
shown in red, and injury causes are shown in green
eFigure 6a. Top ranked cancers by absolute cases for all ages in
males, 2013
eFigure 6b. Top ranked cancers by absolute cases for all ages in
females, 2013
eFigure 6c. Top ranked cancers by absolute death for all ages in
males, 2013
eFigure 6d. Top ranked cancers by absolute death for all ages in
females, 2013
eFigure 7. Trends in age-standardized incidence rates for lip & oral
cavity cancer, females andmales, global level, developed and
developing countries, 1990-2013
eFigure 8. Trends in age-standardized incidence rates for bladder
cancer, females andmales, global level, developed and developing
countries, 1990-2013
eFigure 9. Trends in age-standardized incidence rates for uterine
cancer, females, global level, developed and developing countries,
1990-2013
eFigure 10. Trends in age-standardized incidence rates for pancreatic
cancer, females andmales, global level, developed and developing
countries, 1990-2013
eFigure 11. Trends in age-standardized incidence rates for brain &
nervous system cancer, females andmales, global level, developed
and developing countries, 1990-2013
eFigure 12. Trends in age-standardized incidence rates for kidney
cancer, females andmales, global level, developed and developing
countries, 1990-2013
eFigure 13. Trends in age-standardized incidence rates for malignant
skin melanoma, females andmales, global level, developed and
developing countries, 1990-2013
eFigure 14. Trends in age-standardized incidence rates for thyroid
cancer, females andmales, global level, developed and developing
countries, 1990-2013
eFigure 15. Trends in age-standardized incidence rates for ovarian
cancer, females, global level, developed and developing countries,
1990-2013
eFigure 16. Trends in age-standardized incidence rates for
gallbladder cancer, females andmales, global level, developed and
developing countries, 1990-2013
eFigure 17. Trends in age-standardized incidence rates for larynx
cancer, females andmales, global level, developed and developing
countries, 1990-2013
eFigure 18. Trends in age-standardized incidence rates for other
pharynx cancer, females andmales, global level, developed and
developing countries, 1990-2013
eFigure 19. Trends in age-standardized incidence rates for multiple
myeloma, females andmales, global level, developed and
developing countries, 1990-2013
eFigure 20. Trends in age-standardized incidence rates for Hodgkin
lymphoma, females andmales, global level, developed and
developing countries, 1990-2013
eFigure 21. Trends in age-standardized incidence rates for
nasopharynx cancer, females andmales, global level, developed and
developing countries, 1990-2013
eFigure 22. Trends in age-standardized incidence rates for testicular
cancer, males, global level, developed and developing countries,
1990-2013
eFigure 23. Trends in age-standardized incidence rates for
mesothelioma, females andmales, global level, developed and
developing countries, 1990-2013
eTable 1. Sources for cancer incidence andMI ratio data by country
and registry
eTable 2. Number of site years for cause of death data by source
eTable 3. List of International Classification of Diseases (ICD) codes
mapped to the Global Burden of Disease cause list for cancer
eTable 4. Undefined cancer code categories (ICD-10) and respective
target codes for cancer registry incidence data
eTable 5. Countries within GBD regions
eTable 6. Countries by development status
eTable 7. Results of regression analysis for undefinedmalignant
neoplasms of the lip, oral cavity and pharynx (C14) by age group and
region, male
eTable 8. Carcinoma in situ, neoplasm of uncertain behavior
and benign neoplasm assigned to GBD cancer in CoD
redistribution
eTable 9. Increase in mortality after redistributing benign, in situ
neoplasms or neoplasms of uncertain behavior to respective cancer
by different years and ICD coding system
eTable 10. Increase in mortality estimates for the year 2008 after
redistribution of different categories of garbage code for all
countries using ICD-10 in 2008
eTable 11. Covariates selected for CODEm for each GBD cancer
group
eTable 12. Results for CODEmmodel testing
eTable 13. Sources of procedure sequelae data
eTable 14. Reference life expectancy
eTable 15. ICD-10 codes for "other cancer" group
eTable 16a. Decomposition of trends in incidence, developed
countries, both sexes, 1990 to 2013
eTable 16b. Decomposition of trends in incidence, developing
countries, both sexes, 1990 to 2013
eTable 17. Probability of developing cancer within selected age
intervals, global, by sex, 2010-2013
The Global Burden of Cancer 2013 Special Communication Clinical Review& Education
jamaoncology.com (Reprinted) JAMAOncology July 2015 Volume 1, Number 4 507
Downloaded From: https://jamanetwork.com/ by a Iran University of Medical Sciences User  on 12/07/2019
Copyright 2015 American Medical Association. All rights reserved.
In the third step, the MI ratios were applied to cancer inci-
dencedata to transform incidencedata tomortality estimates.Mor-
tality data from cancer registries were only used to generateMI ra-
tiosanddidnotcontribute to thecancermortalityestimates toavoid
counting the cancer registry data twice. eTable 1 in the Supplement
lists which cancer registry data were used for MI ratio estimation.
The incidence-based mortality estimates became part of the GBD
CoD (cause of death) database. Themethods used to generate the
CoD database are reported in detail elsewhere.1 In brief, all pub-
lished andunpublisheddata relevant to estimating causes of death
for 188 countries from 1980 to 2013 were identified. The sources
includevital registration systems, verbal autopsy studies, andother
sources (eTable 2 in the Supplement). Cancer registry data contrib-
uted37%to thecancer-specific data in theCoDdatabase; theother
sources contributed 63%.
In the fourth step, the CoD database mortality data (including
the cancer incidence data transformed to mortality estimates
through the use of MI ratios) were used as input into the Cause of
DeathEnsembleModel (CODEm) toestimate thenumberofdeaths
attributable to each cancer assessed in the analysis.25 The CODEm
resultswere adjusted using CoDcorrect, an algorithm that uses un-
certaintydistributionsaroundcause fractionestimates foreachGBD
causeof death to scale estimates to all-causemortality estimates in
each country, year, age, and sexgroup. Thesedeathestimateswere
used to calculate years of life lost (YLLs).
The fifth step was to apply MI ratios to CoDcorrect death esti-
mates to obtain cancer incidence estimates for each country, year,
age, and sex group.
In the sixth step,MI ratioswere transformed into an access-to-
carevariable to scale countriesbetweena theoretical best-caseand
worst-case survival to generate relative survival curves. The rela-
tive survivalwas thenadjusted forbackgroundmortality usingGBD
life-tables, and absolute survival rates were estimated.
In step 7, the absolute survival estimates were used to gener-
ate 10-year cancerprevalenceestimates. Total prevalencewas sub-
divided into general cancer sequelae like (1) diagnosis and treat-
ment, (2)metastaticphase, and (3) terminalphase for theestimated
deaths.After these3 sequelaewere assigned, the remainingpreva-
lent timewas considered remission. Prevalence for cancer-specific
sequelae for breast cancer (mastectomy), larynx cancer (laryngec-
tomy), colon and rectum cancer (stoma), bladder cancer (inconti-
nence), andprostate cancer (impotenceand incontinence)wasalso
estimated. To calculate years lived with disability (YLDs), each se-
quelawasmultipliedwith specificdisabilityweights,whichwerede-
rived from population-based surveys.11,26 Disability-adjusted life-
years (DALYs),whichcombinehealth losswithprematuremortality,
were calculated by using the sum of YLLs and YLDs.
This analysis does not provide estimates for NMSC or KS be-
cause NMSC is an exceptional cancer with a very high incidence,
which is usually not collected by cancer registries, and lowmortal-
ity, and KS is attributed to human immunodeficiency virus in the
GBD framework.
Results
Global Incidence, Mortality, and DALYs
In2013, therewere 14.9million incidentcancer casesworldwideand
8.2million cancerdeaths asdetailed inTable 1. Cancer caused 196.3
millionDALYs in 2013 (web table 9); 56%of incident cases, 62%of
deaths, and 70% of DALYs occurred in developing countries. eFig-
ure 5 in the Supplement shows that between 1990 and 2013, the
proportionofdeaths fromnoncommunicablediseases (NCDs) sub-
stantially increased (from 57% in 1990 to 70% in 2013), with a de-
crease indeathsdue to communicable,maternal, neonatal, andnu-
tritionaldiseases (from34%in1990to22%in2013).Theproportion
of cancerdeathsaspartof all deathshas increased from12%in 1990
to 15% in 2013. Between 1990 and 2013, absolute DALYs due to all
cancers (excludingNMSC andKS) for both sexes increased by 29%
globally, by 10% indeveloped countries, andby40% indeveloping
countries. Age-standardized DALYs decreased by 20% globally,
by21% indevelopedcountries, andby 18% indeveloping countries
(web table 9).
Menweremore likely todevelop cancerbetweenbirth andage
79years,with 1 in3menand 1 in5womendeveloping cancerworld-
wide, as detailed in eTable 17 in the Supplement. In 2013, the can-
cerswith thehighest incidenceonaglobal scale formenwerepros-
tate cancer (1.4 million), tracheal, bronchus, and lung (TBL) cancer
(1.3 million), and colon and rectum cancer (873 000), as detailed
inTable 1. The top3causesof cancerdeathandDALYs formenwere
TBL cancer (1.2 million deaths, 24.9 million DALYs), liver cancer
(564 000 deaths, 15.2 million DALYs), and stomach cancer
(530 000 deaths, 11.7 million DALYs) (Table 1; web table 6). For
women, the cancerswith the highest incidencewere breast cancer
(1.8 million), colon and rectum cancer (700 000), and TBL cancer
(535 000). The top 3 causes of cancer death for womenwere TBL
cancer (485 000), breast cancer (464 000), and colon and rec-
tumcancer (357 000) (Table 1). In 2013, the top3 causes forDALYs
in women were breast cancer (13.1 million), TBL cancer (9.8 mil-
lion), and cervical cancer (6.9million) (web table 3).
The contribution of different cancers to total incidence and
death by age group is shown in Figure 1. Brain and nervous system
cancer,Hodgkin lymphoma,non-Hodgkin lymphoma (NHL), leuke-
mia, andthecombined“othercancer”group(agroupcontaining rare
cancers like malignant neoplasm of bone and articular cartilage of
limbs,malignant neoplasmof thymus, and others—see eTable 15 in
the Supplement for a full list of ICD codes) are the main contribu-
tors tocancer incidence inchildrenandadolescents (age<20years).
Brain andnervous systemcancer,NHL, leukemia, and cancers from
theothercancergroupcausemostof thecancerdeaths in thisyoung
age group. In young andmiddle-aged adults breast, cervical, colon
and rectum cancer, brain and nervous system cancer, and cancers
Box 3.WebTable Addresses
Web table 1. http://ja.ma/healthdataorg_webtable1
Web table 2. http://ja.ma/healthdataorg_webtable2
Web table 3. http://ja.ma/healthdataorg_webtable3
Web table 4. http://ja.ma/healthdataorg_webtable4
Web table 5. http://ja.ma/healthdataorg_webtable5
Web table 6. http://ja.ma/healthdataorg_webtable6
Web table 7. http://ja.ma/healthdataorg_webtable7
Web table 8. http://ja.ma/healthdataorg_webtable8
Web table 9. http://ja.ma/healthdataorg_webtable9
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from the other cancer group add the largest fraction to total inci-
dence. Stomach, liver, TBL, and breast cancer contribute themost
to cancerdeaths. Forolder adults (>54years) stomach, TBL, breast,
prostate, and colon and rectum cancers are the biggest contribu-
tors to incidence. Stomach, liver, TBL, and colon and rectum can-
cer cause themajority of cancer deaths in older adults.
For all cancers combined (excluding NMSC and KS), ASIRs be-
tween 1990and2013 increased in 153of 188countries (Figure2A),
withmanycountries inpartsofNorthernAfrica and theMiddleEast,
sub-Saharan Africa, Southeast Asia, and Oceania having experi-
enced increases of over 20%.However, ASDRs for all cancers com-
bined (excludingNMSCandKS)decreasedwithin that timeframe in
126 of 188 countries (Figure 2B).
Top 10 Cancers (Ranked by the Highest Number
of Incident Cases Globally in 2013)
Tracheal, Bronchus, and Lung Cancer
In 2013, there were an estimated 1.8 million incident cases of TBL
cancer and 1.6 million deaths. Tracheal, bronchus, and lung cancer
caused 34.7 million DALYs in 2013, with 62% occurring in develop-
ing countries and 38% occurring in developed countries (web
table 9). Men were more likely to develop lung cancer than
women, with 1 in 18 men and 1 in 51 women being diagnosed
between birth and age 79 years. Tracheal, bronchus, and lung can-
cer has the second highest absolute incidence globally as well as in
developing countries and ranks fourth in developed countries
(Figure 3). It was the most common cause of cancer death by
Table 1. 2013 Incidence and Deaths for All Cancers and 28 Cancer Groupsa
Cancer
Incident Cases, Global
(Thousands)
ASIR, Both Sexes
(per 100 000)
Deaths, Global
(Thousands)
ASDR, Both Sexes
(per 100 000)
Total Male Female Developing Developed Global Total Male Female Developing Developed Global
All except NMSC
and KS
14 943 8048 6894 190.4 327.9 237.4 8196 4723 3473 123.0 147.9 133.1
Esophageal 442 309 133 8.9 3.9 7.1 440 308 132 9.1 3.8 7.2
Stomach 984 630 354 16.9 14.4 16.1 841 530 311 15.3 11.1 13.8
Liver 792 559 233 14.7 7.4 12.5 818 564 254 15.6 7.3 13.0
Larynx 177 155 22 2.8 2.9 2.8 88 75 12 1.5 1.3 1.4
Tracheal, bronchus
and lung
1798 1263 535 25.2 37.7 29.4 1640 1155 485 24.1 32.9 27.0
Breast 1804 25 1779 21.0 40.8 27.4 471 7 464 5.9 10.1 7.4
Cervical 485 … 485 8.0 5.0 7.1 236 … 236 4.3 2.2 3.6
Uterine 353 … 353 4.2 7.7 5.4 68 … 68 0.9 1.4 1.1
Prostate 1442 1442 … 14.3 43.2 24.3 293 293 … 3.6 7.4 5.2
Colon and rectum 1573 873 700 16.3 42.3 25.8 771 414 357 9.4 18.2 12.8
Lip and oral cavity 409 275 134 6.7 6.0 6.4 135 87 48 2.3 1.9 2.1
Nasopharynx 84 62 22 1.5 0.4 1.2 60 43 17 1.2 0.3 0.9
Other pharynx 140 117 22 2.0 2.6 2.1 79 63 16 1.3 1.2 1.2
Gallbladder and
biliary tract
186 79 107 2.5 3.8 3.1 140 54 86 2.0 2.7 2.3
Pancreatic 350 184 166 3.7 9.5 5.8 352 185 167 3.7 9.6 5.9
Malignant skin melanoma 272 143 130 1.5 10.8 4.2 57 32 25 0.4 1.9 0.9
Ovarian 226 … 226 2.4 5.6 3.5 158 … 158 1.8 3.7 2.5
Testicular 59 59 … 0.6 1.8 0.8 8 8 … 0.1 0.1 0.1
Kidney 295 195 99 2.3 9.7 4.7 134 87 47 1.3 3.7 2.2
Bladder 401 312 89 3.2 12.8 6.7 174 130 44 2.4 3.7 3.0
Brain and nervous system 305 167 137 4.1 5.9 4.5 204 118 86 2.9 3.8 3.1
Thyroid 226 50 176 2.7 4.9 3.3 34 12 21 0.5 0.6 0.6
Mesothelioma 34 24 10 0.4 0.8 0.5 34 24 10 0.4 0.8 0.5
Hodgkin lymphoma 93 56 38 1.2 1.9 1.3 24 14 10 0.4 0.4 0.4
Non-Hodgkin lymphoma 465 264 202 5.2 11.3 7.3 226 133 92 2.9 4.5 3.6
Multiple myeloma 117 64 53 1.0 3.5 1.9 79 42 37 0.7 2.3 1.3
Leukemia 414 243 172 5.1 8.1 6.3 265 149 116 3.5 4.8 4.1
Other neoplasms 1015 496 518 12.0 23.0 15.7 370 195 175 5.4 6.2 5.8
Abbreviations: ASDR, age-standardized death rate; ASIR, age-standardized
incidence rate; DALYs, disability-adjusted life-years; GBD, Global Burden of
Disease; ICD-9, International Classification of Diseases, Ninth Revision;
ICD-10, International Statistical Classification of Diseases and Related Health
Problems, Tenth Revision; KS, Kaposi sarcoma; NMSC, nonmelanoma skin
cancer; YLDs, years lived with disability; YLLs, years of life lost.
a Cancer groups are defined based on ICD codes and include all codes pertaining
to neoplasms (ICD-9 140-239; ICD-10 C00-D49) except for NMSC and KS.
eTable 3 in the Supplement details how the original ICD codes weremapped to
the standardized GBD cause list.1 Detailed results for incidence, mortality,
YLDs, YLLs, and DALYs by country development status (developed vs
developing), region, and country are reported in web tables 1 through 9. Sums
might not total precisely due to rounding.
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absolute cases globally as well as in developing and developed
regions (Figure 4).
As detailed in web tables 4 and 5, ASIRs per 100 000 for men
were the lowest in western sub-Saharan Africa (with ASDRs per
100 000 reported for comparison) (ASIR, 6.33; ASDR, 6.36), east-
ern sub-Saharan Africa (ASIR, 8.01; ASDR, 8.52), and central sub-
SaharanAfrica (ASIR, 12.77; ASDR, 13.08) and the highest in central
Europe (ASIR, 66.10; ASDR, 63.87), east Asia (ASIR, 64.68; ASDR,
60.13), and high-income North America (ASIR, 61.5; ASDR, 51.02).
Forwomen in2013, incidence ratesper 100 000were the low-
est inwestern sub-SaharanAfrica (withdeath ratesper 100 000re-
ported for comparison) (ASIR, 2.76; ASDR, 2.96) followed by east-
ernsub-SaharanAfrica (ASIR,3.15;ASDR,3.51), andsouthAsia (ASIR,
3.80; ASDR, 4.12) and the highest in high-income North America
(ASIR, 41.83; ASDR, 31.33), Australasia (ASIR, 25.23; ASDR, 20.46),
and east Asia (ASIR, 22.88; ASDR, 22.16) (web tables 1 and 2).
eFigure6aandc in theSupplement shows that TBLcancerwas
thecancerwith themost incidentcases formen in40countries,with
a predominance in central and eastern Europe, Asia, and northern
Africa, andTBLwas themost commoncause for cancerdeath in 103
countries. For women, TBL cancer was themost common cause of
cancer death in Albania, Andorra, Australia, Brunei, Canada, China,
Cuba, Denmark, United Kingdom, Hungary, Ireland, Iceland, Cam-
bodia, SouthKorea, Laos,Myanmar,Netherlands,NewZealand,Po-
land, North Korea, Singapore, Timor-Leste, Taiwan, and theUnited
States (eFigure 6d in the Supplement).
Figure 1. Age-Specific Global Contributions of Cancer Types to Total Cancer Incidence andMortality, 2013
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For International Classification of Diseases codes included in the other neoplasms group, see eTable 15 in the Supplement.
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Figure 2. Relative Changes in Age-Standardized Incidence and Death Rates in Both Sexes for All Cancers Except NMSC and KS in 188 Countries
From 1990 to 2013
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Figure 3. Cancers Ranked by Number of Incident Cases in Both Sexes, Globally, by Development Status, and in the 50Most Populous Countries, 2013
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Colors correspond to the ranking, with dark red as themost common cancer
and dark green as the least common cancer for the location indicated. Rankings
do not include the “other cancer” group (eTable 15 in the Supplement). The
numbers inside each box indicate the ranking.
a Developing country.
bDemocratic Republic of Congo.
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Figure 4. Cancers Ranked by Number of Deaths in Both Sexes, Globally, by Development Status, and in the 50Most Populous Countries, 2013
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Colors correspond to the ranking, with dark red as the cancer with themost
deaths and dark green as the cancer with the least deaths for the location
indicated. Rankings do not include the “other cancer” group (eTable 15 in the
Supplement). The numbers inside each box indicate the ranking.
a Developing country.
bDemocratic Republic of Congo.
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Between 1990 and 2013, TBL cancer remained the leading
cause of cancer YLLs (Figure 5). A decrease in incidence rates
between 1990 and 2013 with stable population size and age struc-
ture would have resulted in a 13% decrease in incident cases
(Table 2). However, overall incident cases increased by 62%
because of population growth and aging. The ASIRs per 100 000
for both sexes between 1990 and 2013 decreased by 6% at the
global level (31.12 to 29.36), by 14% for developed countries (43.81
to 37.74) but increased by 9% in developing countries (23.04 to
25.18) (web table 7).
At the global level, incidence for women has risen slowly,
whereas rates have fallen for men since the mid-1990s (Figure 6).
The same trends can be seen in developed regions. However, in
developing regions, rates are still increasing for men. Age-
standardizedDALYrates forbothsexesbetween1990and2013have
decreased by 17% at the global level, by 23% for developed coun-
tries, and by 7% for developing countries (web table 9).
Breast Cancer
Since only 1% of breast cancer cases in 2013 occurred in men, only
femalebreast cancer isdiscussedherein. In2013, therewere 1.8mil-
lion incidentcasesofbreastcancerand464thousanddeaths.Breast
cancer caused 13.1millionDALYs in2013 (web table3),with63%oc-
curring in developing countries and 37% occurring in developed
countries.One in 18womendevelopedbreast cancerbetweenbirth
and age 79 years.
As detailed in web tables 1 and 2, in 2013, ASIRs per 100 000
were the lowest in western sub-Saharan Africa (with ASDRs per
100 000reported for comparison) (ASIR,28.24;ASDR, 10.65), east
Asia (ASIR,33.52;ASDR,6.87),andeasternsub-SaharanAfrica (ASIR,
33.67; ASDR, 13.71) and thehighest inOceania (ASIR, 133.38;ASDR,
28.89), high-incomeNorthAmerica (ASIR, 111.01;ASDR, 19.07), and
Australasia (ASIR, 91.12; ASDR, 19.63).
Breast cancer was the cancer with the highest incidence for
women in 161 countries (eFigure 6b in the Supplement) and the
Figure 5. Cancers Ranked Globally and for Both Sexes by Absolute Years of Life Lost (YLLs) Including the Percentage Change in Absolute YLLs
and the Percentage Change in the Age-Standardized YLL Rate Between 1990 and 2013
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The “other cancers” group (eTable 15 in the Supplement) is not included here because it contains multiple different types of cancers. Solid lines connecting the 1990
and 2013 charts indicate increased or unchanged rank for the connected cancers; dotted lines indicated decreased rank.
Clinical Review& Education Special Communication The Global Burden of Cancer 2013
514 JAMAOncology July 2015 Volume 1, Number 4 (Reprinted) jamaoncology.com
Downloaded From: https://jamanetwork.com/ by a Iran University of Medical Sciences User  on 12/07/2019
Copyright 2015 American Medical Association. All rights reserved.
most common cause for cancer deaths in women in 98 countries
(eFigure 6d in the Supplement).
Figure 5 shows that breast cancer ranked sixth in 1990 for can-
cer YLLs, but it moved to fifth place in 2013. Compared with 1990,
in2013, incident cases increasedby898 000(99%increase).With
stable population size and age structure, breast cancer incidence
would have increased by 26% due to increasing incidence rates.
Population aging with unchanged incidence rates or population
growth would have led to a 38% increase in incidence (Table 2).
Globally, female breast cancer incidence has been continu-
ously increasing,witha slower increase since2000(Figure7). Even
though femalebreast cancer incidence is lower indeveloping coun-
tries, it is increasing rapidly compared with developed countries,
where rateshavebeenstable todecliningsince theearly2000s.Be-
tween 1990 and 2013, ASIRs per 100 000 have increased by 17%
globally (44.36 to 51.73), by 46% in developing countries (27.74 to
40.40)andby8%indevelopedcountries (69.75to74.98)(webtable
1).Age-standardizedDALYrateshavedecreasedby17%at theglobal
Table 2. Decomposition Analysis of Cancer Trends in Global Incidence, Both Sexes, 1990 to 2013
Cancera
Incident Cases, No. Expected Incident Cases, 2013, No. Change in Incident Cases, 1990 to 2013, %
1990 2013
Given Population
Growth Alone
Given Population
Growth and Aging
Due to
Population
Growthb
Due to Change
in Age
Structurec
Due to Change
in Incidence
Ratesd
All except NMSC and KS 8 510 588 14 942 583 11 486 507 14 515 059 35.0 35.6 5.0
Esophageal 303 510 441 767 409 640 530 592 35.0 39.9 −29.3
Stomach 800 136 984 206 1 079 922 1 401 995 35.0 40.3 −52.2
Liver 465 014 792 203 627 617 800 507 35.0 37.2 −1.8
Larynx 137 785 176 687 185 964 238 499 35.0 38.1 −44.9
Tracheal, bronchus
and lung
1 113 162 1 798 179 1 502 405 1 937 791 35.0 39.1 −12.5
Breast 906 618 1 804 209 1 223 637 1 568 145 35.0 38.0 26.0
Cervical 447 344 485 297 603 768 747 821 35.0 32.2 −58.7
Uterine 216 793 353 117 292 599 375 986 35.0 38.5 −10.5
Prostate 454 412 1 442 460 613 308 801 983 35.0 41.5 140.9
Colon and rectum 818 440 1 572 590 1 104 626 1 443 985 35.0 41.5 15.7
Lip and oral cavity 238 789 409 360 322 287 413 567 35.0 38.2 −1.8
Nasopharynx 67 658 83 702 91 316 112 072 35.0 30.7 −41.9
Other pharynx 80 691 139 567 108 907 140 604 35.0 39.3 −1.3
Gallbladder and
biliary tract
136 503 186 253 184 234 242 255 35.0 42.5 −41.0
Pancreatic 183 076 350 361 247 093 323 423 35.0 41.7 14.7
Malignant skin melanoma 151 601 272 481 204 612 254 748 35.0 33.1 11.7
Ovarian 137 417 226 204 185 467 234 642 35.0 35.8 −6.1
Testicular 37 982 59 279 51 263 56 101 35.0 12.7 8.4
Kidney 142 463 294 501 192 279 241 697 35.0 34.7 37.1
Bladder 263 307 401 174 355 378 466 220 35.0 42.1 −24.7
Brain and central
nervous system
193 980 304 528 261 809 293 291 35.0 16.2 5.8
Thyroid 115 627 225 566 156 058 187 946 35.0 27.6 32.5
Mesothelioma 16 972 33 744 22 906 29 561 35.0 39.2 24.6
Hodgkin lymphoma 103 249 93 345 139 353 142 599 35.0 3.1 −47.7
Non-Hodgkin lymphoma 226 661 465 488 305 918 373 548 35.0 29.8 40.6
Multiple myeloma 62 738 116 947 84 676 110 140 35.0 40.6 10.8
Leukemia 297 404 414 443 401 398 437 862 35.0 12.3 −7.9
Other neoplasms 391 255 1 014 928 528 066 607 480 35.0 20.3 104.1
Abbreviations: GBD, Global Burden of Disease; ICD-9, International
Classification of Diseases, Ninth Revision; ICD-10, International Statistical
Classification of Diseases and Related Health Problems, Tenth Revision;
KS, Kaposi sarcoma; NMSC, nonmelanoma skin cancer; YLDs, years lived with
disability; YLLs, years of life lost.
a Cancer groups are defined based on ICD codes and include all codes pertaining
to neoplasms (ICD-9 140-239; ICD-10 C00-D49) except for NMSC and KS.
eTable 3 in the Supplement details how the original ICD codes weremapped to
the standardized GBD cause list.1
b To estimate the effect of population growth we applied the population size of
2013 onto the rate, sex, and age structure of 1990. Since the global population
grew by 35% between 1990 and 2013, and rates and age structure remained
the same as in 1990, incidence due to all cancers increased by 35% in this
counterfactual scenario.
c To estimate the effect of aging on incident cases we applied the age structure
of 2013 onto the rate, sex distribution, and population size of 1990. The
change in incident cases reported herein shows the proportion of the change
in incident cases between 1990 and 2013 that can be attributed to the
changing age structure of the population.
d To estimate the effect of changing incidence rates on the incident cases we
applied the incidence rates for 1990 onto the population size and age
structure of 2013. The change in incident cases reported herein shows the
proportion of the change in incident cases between 1990 and 2013 that can be
attributed to a change in incidence rates.
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level, by 25% for developed countries, and by 3% for developing
countries (web table 3).
Colon and Rectum Cancer
In2013, therewere1.6million incidentcasesofcolonandrectumcan-
cer, and it caused 771 000deaths. Colon and rectum cancer caused
15.8millionDALYs in2013,with56%occurring indevelopingcountries
and44%occurringindevelopedcountries(webtable9).Theprobabil-
ity of developing colon and rectum cancer before age 79 years was
higher formen than forwomen (1 in 27men; 1 in 43women).
Globally, colon and rectum cancer ranked third for cancer inci-
dence and fourth for cancer death in 2013 (Figures 3 and 4). For
developed countries it ranked second for incidence and mortality,
and in developing countries it ranked fourth for both incidence
and mortality.
As detailed in in web tables 4 and 5, the 2013 incidence rates
per 100 000formenwere the lowest inwesternsub-SaharanAfrica
(with ASDRs per 100 000 reported for comparison) (ASIR, 9.12;
ASDR,6.51), southAsia (ASIR, 10.26;ASDR,6.07), andeastern sub-
Saharan Africa (ASIR, 12.73; ASDR, 9.91) and the highest in Austral-
asia (ASIR, 60.64; ASDR, 22.29), high-income Asia Pacific (ASIR,
58.48; ASDR, 22.56), and western Europe (ASIR, 55.69; ASDR,
24.24). For women, incidence rates per 100 000 in 2013were the
lowest in south Asia (with ASDRs per 100 000 reported for com-
parison) (ASIR,6.04;ASDR,3.98),westernsub-SaharanAfrica (ASIR,
6.95;ASDR,5.49),andeasternsub-SaharanAfrica (ASIR,9.86;ASDR,
8.57) and thehighest inAustralasia (ASIR,43.75;ASDR, 15.95), high-
incomeNorth America (ASIR, 39.95; ASDR, 13.12), andwestern Eu-
rope (ASIR, 33.96;ASDR, 15.01) (web tables 1 and2). eFigure6aand
c in theSupplementshowthatcolonandrectumcancerwas thecan-
cer with the highest incidence in 2013 for men in Bulgaria, Brunei,
Hungary, Japan, Kuwait, Saudi Arabia, Singapore, Slovakia, and
Taiwan and the most common cause of cancer death in Ethiopia
andTanzania. Forwomen, colon and rectumcancerwas the cancer
with thehighest incidence in Japan and themost commoncauseof
death in Spain, Japan, Norway, Portugal, and Sweden (eFigure 6b
and d in the Supplement).
Figure 5 shows that colon and rectum cancer remained the
fourth leadingcause forcancerYLLsbetween1990and2013.Table2
details how in 2013 almost twice as many people were diagnosed
with colon and rectumcancer as in 1990 (818 000 in 1990, 1.6mil-
lion in 2013).Most of this increase canbeexplainedby anaging and
growing population, but even with the same population size and
structure, colon and rectum cancer cases would have increased by
16%between 1990 and 2013 due to an increase in incidence rates.
Figure8 shows thatworldwideASIR for colon and rectumcan-
cer for women between 1990 and 2013 remained stable but in-
creased formen. As detailed inweb tables 1 and 4, ASIRs increased
by 1% between 1990 and 2013 for women and by 16% for men. In
developed countries, ASIRs decreased by 3% in women and in-
creased by 8% inmen. However, in developing regions, rates have
risen rapidly, with a 53% increase in men and a 31% increase in
women between 1990 and 2013. Between 1990 and 2013, age-
standardized DALY rates for both sexes have decreased by 15% at
the global level, by 18% in developed countries, and by 2% in de-
veloping countries (web table 9).
Prostate Cancer
In 2013, therewere 1.4million incident casesof prostate cancer and
293 000 deaths. Prostate cancer caused 4.8 million DALYs glob-
Figure 6. Trends in Age-Standardized Incidence Rates for Tracheal, Bronchus, and Lung Cancer, 1990-2013
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Figure 7. Trends in Age-Standardized Incidence Rates
for Female Breast Cancer, 1990-2013
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ally in 2013, with 57% occurring in developed countries, and 43%
occurring in developing countries (web table 9). The probability of
developing prostate cancer is detailed in eTable 17 in the Supple-
ment,with 1 in 15mendevelopingprostatecancerbetweenbirthand
age 79 years.
Ourwebtables4and5detailhowincidenceratesper100 000in
2013werethelowest insouthAsia(withASDRsper100 000reported
forcomparison) (ASIR,9.9;ASDR,2.39),eastAsia (ASIR, 13.99;ASDR,
3.43),andcentralAsia(ASIR,25.57;ASDR,7.91)andthehighest inhigh-
incomeNorthAmerica(ASIR,184.23;ASDR,19.7),theCaribbean(ASIR,
154.97;ASDR,49.05), andAustralasia (ASIR, 144.81; ASDR, 26.53).
eFigure 6a and c in the Supplement shows that in 2013, pros-
tatecancerwas thecancerwith thehighest incidence formen in 104
of 188 countries, and the leading cause of cancer death for men in
24 countries.
Prostate cancer ranked 15th for cancer YLLs in 1990 and 13th
in 2013 as can be seen in Figure 5. Table 2 details how the increas-
ing incidence together with an aging and growing population have
ledtoamorethan3-fold increase inprostatecancercasessince 1990
(454 000 in 1990, 1.4 million in 2013). The ASIR for prostate can-
cer had the steepest increase between 1990 and 2013 of all can-
cers inmen (Figure 9). As listed inweb table 4, ASIRs per 100 000
increased by69%globally (32.42 to 54.68), by 135% in developing
countries (13.29 to31.25), andby63%indevelopedcountries (61.51
to 100.29). Prostate cancer incidence rates are still lower in devel-
opingcountries than indevelopedcountries, butbecauseof a faster
increase in rates in developing countries, the gap decreased be-
tween 1990 and 2013 from a 4-fold to a 3-fold difference. During
the same timeframe, age-standardizedDALY rates have decreased
by3%at theglobal level andby9%indevelopedcountriesbuthave
increased by 28% in developing countries (web table 9).
Stomach Cancer
In 2013, therewere984 000 incident casesof stomachcancer and
841 000deaths. Stomachcancer caused 17.9millionDALYs in2013,
with 77% occurring in developing countries, and 23% occurring in
developedcountries (webtable9).One in36menand1 in84women
developed stomach cancer before age 79 years. Globally, stomach
cancer rankedfifth forcancer incidenceandsecondforcancerdeaths
in 2013 (Figures 3 and 4). For developed countries, it ranked fifth
for incidence and third formortality, and in developing countries, it
ranked third for both incidence andmortality.
TheASIRs andASDRsper 100 000 in2013 forboth sexeswere
higher in developing countries vs developed countries (ASIR, 16.9
vs 14.38; ASDR, 15.33 vs 11.07) (web tables 7 and 8). As detailed in
web tables 4 and 5, the 2013 incidence rates per 100 000 formen
were the lowest in southern sub-Saharan Africa (with ASDRs per
100 000reported for comparison) (ASIR,8.27;ASDR,6.97), south
Asia (ASIR,9.01;ASDR,9.19), andeastern sub-SaharanAfrica (ASIR,
9.12; ASDR, 10.01) and the highest in high-income Asia Pacific
(ASIR, 42.31; ASDR, 31.61), east Asia (ASIR, 39.16; ASDR, 34.12), and
Andean Latin America (ASIR, 32.61; ASDR, 27.96). Forwomen, inci-
dence rates per 100 000 in 2013were the lowest in southern sub-
Saharan Africa (with ASDRs per 100 000 reported for compari-
son) (ASIR, 4.54; ASDR, 3.93), high-income North America (ASIR,
4.65;ASDR, 2.94), andAustralasia (ASIR, 5.37; ASDR, 3.84) and the
highest in Andean Latin America (ASIR, 24.62; ASDR, 21.69), high-
incomeAsiaPacific (ASIR, 20.00;ASDR, 14.86), andeastAsia (ASIR,
14.78; ASDR, 13.37) (web tables 1 and 2).
Figure 8. Trends in Age-Standardized Incidence Rates for Colon and Rectum Cancer, 1990-2013
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Figure 9. Trends in Age-Standardized Incidence Rates
for Prostate Cancer, 1990-2013
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Stomach cancer was the cancer with the highest absolute inci-
dence in 2013 for men in Honduras, Iran, Kyrgyzstan, and Tajiki-
stan and the leading cause of cancer death in Bolivia, Central Afri-
can Republic, Chile, Democratic Republic of the Congo, Congo,
Colombia, Cape Verde, Costa Rica, Ecuador, Guatemala, Honduras,
Iran, Kyrgyzstan, Oman, Peru, El Salvador, and Tajikistan (eFigure
6a and c in the Supplement). For women, it was the cancer with
the most incident cases in Cape Verde and the leading cause of
cancer death in Afghanistan, Bolivia, Cape Verde, Ecuador, Guate-
mala, Honduras, Peru, Tajikistan, and Vietnam (eFigure 6b and d in
the Supplement).
Stomach cancer decreased from the second highest cause for
crude cancer YLLs in 1990 to the third highest in 2013, with a 2.5%
decrease in absolute YLLs due to cancer (Figure 5). If the popula-
tion age structure and size had remained the same in 2013 as it
was in 1990, incidence would have dropped by 52.2% due to
decreasing rates (Table 2). As illustrated in Figure 10, ASIRs have
dropped substantially since 1990, Between 1990 and 2013 age-
standardized DALYs for both sexes decreased by 42% globally, by
49% in developed countries, and by 40% in developing countries
(web table 9).
Liver Cancer
In 2013, therewere 792 000 incident cases of liver cancer globally
and818 000deaths.Livercancercaused20.9millionDALYs in2013,
with 86% occurring in developing countries and 14% occurring in
developed countries (web table 9). Liver cancer is more common
inmen,with 1 in 45menbeing diagnosed before age 79 years com-
paredwith 1 in 121women.Globally, liver cancer rankedsixth for can-
cer incidenceandthird forcancerdeath in2013asshown inFigures3
and4. For developed countries it ranked 11th for incidence and sev-
enth formortality, and in developing countries it ranked fifth for in-
cidence and second for mortality.
The ASIRs and ASDRs for liver cancer per 100 000 in 2013 for
both sexeswerehigher indeveloping countries vsdevelopedcoun-
tries (ASIR, 14.72 vs 7.42; ASDR, 15.59 vs 7.26) (web tables 7 and8).
As web tables 4 and 5 detail, in 2013 incidence rates per 100 000
for menwere the lowest in tropical Latin America (with ASDRs per
100 000 reported for comparison) (ASIR, 5.86; ASDR, 6.45), east-
ern Europe (ASIR, 6.07; ASDR, 6.46), and Australasia (ASIR, 6.26;
ASDR,5.69)andthehighest ineastAsia (ASIR,36.66;ASDR,36.88),
western sub-Saharan Africa (ASIR, 30.53; ASDR, 33.68), and high-
income Asia Pacific (ASIR, 30.16; ASDR, 29.48). For women inci-
dence rates in 2013 per 100 000 were the lowest in eastern Eu-
rope (ASIR, 2.52;ASDR, 2.85), Australasia (ASIR, 2.72;ASDR, 2.68),
and high-income North America (ASIR, 2.87; ASDR, 2.72) and the
highest inwesternsub-SaharanAfrica (ASIR, 13.17;ASDR, 14.79),east
Asia (ASIR, 11.89;ASDR, 13.09),andOceania (ASIR, 10.01;ASDR, 11.18)
(web tables 1 and 2).
Liver cancerwas themost commonlydiagnosedcancer in2013
for men in Benin, Burkina Faso, Cameroon, Guinea, The Gambia,
Guinea-Bissau, Liberia, Mali, Mongolia, Mauritania, Niger, Senegal,
Sierra Leone, Chad, Togo, Thailand, and Vietnam (eFigure 6a in the
Supplement) and the most common cause of cancer death in Bu-
rundi, Benin, Burkina Faso, Bangladesh, Côte d'Ivoire, Cameroon,
Egypt, Eritrea, Fiji, Ghana, Guinea, The Gambia, Guinea-Bissau,
Liberia, Madagascar, Mali, Mongolia, Mauritania, Niger, Nigeria,
Rwanda, Saudi Arabia, Senegal, Sierra Leone, Chad, Togo, Thai-
land, Taiwan, and Vietnam (eFigure 6c in the Supplement).
For women in 2013, liver cancer was themost commonly diag-
nosed cancer as well as the leading cause of cancer death in Mon-
golia (eFigure 6b and d in the Supplement).
Figure3showsamarkeddifferencebetweenthe50mostpopu-
louscountries for liver cancer incidence rankings.Forexample,while
it ranks inmost of these countries among the top 10 cancers for in-
cidence, it ranks21st inUkraine, 19th inPoland,and18th in theUnited
States, the United Kingdom, Argentina, and Canada.
Liver cancer has increased from the third leading cause for
cancer YLLs in 1990 to the second leading cause in 2013
(Figure 5). Aging and population growth are the drivers of the
increase from 465 000 cases in 1990 to 792 000 cases in 2013
(Table 2). If the population age structure and size had remained
the same in 2013 as they were in 1990, 1.8% fewer cases of liver
cancer would have been diagnosed in 2013 than in 1990. World-
wide, as well as in developing regions, ASIRs appear to have
peaked in the late 1990s, with a slow decrease in rates since 2000
(Figure 11). Between 1990 and 2013, age-standardized DALY rates
for both sexes for liver cancer decreased by 14% at the global
Figure 10. Trends in Age-Standardized Incidence Rates for Stomach Cancer, 1990-2013
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level, by 20% in developing countries, and by 4% in developed
countries (web table 9).
Cervical Cancer
In 2013, 485 000 women were diagnosed with cervical cancer
worldwide, and it caused 236 000 deaths. Cervical cancer caused
6.9million DALYs, with 85% occurring in developed countries and
15% occurring in developing countries. One in 70 women devel-
oped cervical cancer between birth and age 79 years.
The ASIRs and ASDRs per 100 000 in 2013 were higher in
developing countries vs developed countries (ASIR, 15.70 vs 9.58;
ASDR, 8.32 vs 3.96) (web tables 1 and 2). In 2013, incidence rates
per 100 000 were the lowest in Australasia (with ASDRs per
100 000 reported for comparison) (ASIR, 6.83; ASDR, 2.65),
north Africa and Middle East (ASIR, 7.23; ASDR, 3.19) and high-
income North America (ASIR, 7.26; ASDR, 2.84), and the highest in
Oceania (ASIR, 58.4; ASDR, 26.49), eastern sub-Saharan Africa
(ASIR, 31.5; ASDR, 25.57), and western sub-Saharan Africa (ASIR,
30.2; ASDR, 22.3).
Cervical cancer was the most commonly diagnosed cancer in
2013 for women in Afghanistan, Benin, Central African Republic,
Cameroon, Eritrea, Ghana, Guinea, The Gambia, Guinea-Bissau,
Guatemala, Liberia, Lesotho, Mali, Mauritania, Malawi, Niger, Nige-
ria, Nicaragua, Senegal, Sierra Leone, El Salvador, Somalia, Chad,
Togo, Uganda, Zambia, and Zimbabwe (eFigure 6b in the Supple-
ment) and the most common cause of cancer death for women in
Angola, Burundi, Benin, Burkina Faso, Central African Republic,
Côte d’Ivoire, Cameroon, Democratic Republic of the Congo,
Congo, Comoros, Djibouti, Eritrea, Ethiopia, Ghana, Guinea,
Guinea-Bissau, Equatorial Guinea, Indonesia, Kenya, Liberia, Leso-
tho, Madagascar, Mali, Mozambique, Mauritania, Malawi, Niger,
Nigeria, Nicaragua, Papua NewGuinea, Paraguay, Rwanda, Senegal,
Sierra Leone, El Salvador, Somalia, South Sudan, Sao Tome and
Principe, Swaziland, Chad, Togo, Tanzania, Uganda, Zambia, and
Zimbabwe (eFigure 6d in the Supplement).
Cervical cancerwas the eighth leading cause for cancer YLLs in
1990 and the ninth leading cause in 2013, with a 32% decrease in
age-standardized YLLs (Figure 5). Total incidence would have de-
creased by 59% if the population size and age structure had re-
mained the same in 2013 as it was in 1990 due to decreasing inci-
dence rates (Table2).Bothglobally and indeveloping regions,ASIRs
for cervical cancer have decreased (Figure 12). Between 1990
and 2013, age-standardized DALYs decreased globally by 32%, in
developing countries by 36%, and in developed countries by 34%
(web table 3).
Non-Hodgkin Lymphoma
In 2013, there were 465 000 incident cases of NHL and 226 000
deaths. Non-Hodgkin lymphoma caused 6.4 million DALYs in
2013, with 71% occurring in developing countries and 29% occur-
ring in developed countries (web table 9). One in 103men and 1 in
151 women developed NHL cancer between birth and age 79
years.
Globally,NHLrankedeighthforcancer incidenceand11thforcan-
cerdeath in2013(Figures3and4).Fordevelopedcountries, it ranked
seventhfor incidenceandninthformortality,and indevelopingcoun-
tries it ranked 11th for both incidence andmortality.
Asdetailed inweb tables4and5, 2013NHL incidenceand rates
per 100 000 for menwere the lowest in Oceania (with ASDRs per
Figure 11. Trends in Age-Standardized Incidence Rates for Liver Cancer, 1990-2013
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Figure 12. Trends in Age-Standardized Incidence Rates
for Cervical Cancer, 1990-2013
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100 000 reported for comparison) (ASIR, 3.13; ASDR, 1.80), west-
ern sub-Saharan Africa (ASIR, 4.10; ASDR, 3.50), and central Asia
(ASIR, 4.52; ASDR, 3.04) and the highest in high-income North
America (ASIR, 22.09; ASDR, 7.74), Australasia (ASIR, 15.43; ASDR,
7.49), and western Europe (ASIR, 14.19; ASDR, 6.04).
Forwomen,NHL incidence ratesper 100 000 in2013were the
lowest in central Asia (ASIR, 2.35; ASDR, 1.32), western sub-
SaharanAfrica (ASIR, 2.68;ASDR, 1.96), and southAsia (ASIR, 3.27;
ASDR, 2.37) and the highest in high-income North America (ASIR,
15.01; ASDR, 4.79), Australasia (ASIR, 10.74; ASDR, 4.71), andWest-
ern Europe (ASIR, 9.56; ASDR, 3.66) (web tables 1 and 2). Non-
Hodgkin lymphoma was the most commonly diagnosed cancer in
2013 for men in the United Arab Emirates and Qatar (eFigure 6a in
the Supplement).
Non-Hodgkin lymphoma ranked 10th for cancer YLLs in 1990
and 11th in 2013 (Figure 5). More than twice as many cases of NHL
were diagnosed in 2013 as in 1990 (465 000 vs 227 000). Popu-
lationgrowthalonewouldhave increased incidenceby35%;popu-
lation aging alonewould have increased incidence by 30%; and an
increase in incidence rates assuming stable population age struc-
ture and size between 1990 and 2013 would have led to a 41% in-
crease in new cases (Table 2). Figure 13 illustrates the slight in-
crease in ASIRs between 1990 and 2013. On the global level, ASIRs
per 100 000 for both sexes for NHL increased by 26% (5.8 to 7.3),
with a larger increase indeveloping countries (44%,3.6 to5.2) than
in developed countries (23%, 9.2 to 11.3) (web table 7).
During this timeframe, age-standardized DALY rates for both
sexesdecreasedby3%at theglobal level,by8%indevelopingcoun-
tries, and increased by 2% in developing countries (web table 9).
Esophageal Cancer
In 2013 there were 442 000 new cases of esophageal cancer and
440 000 deaths. Esophageal cancer caused 9.8 million DALYs in
2013, with 84% occurring in developing countries and 16% occur-
ring in developed countries (web table 9). Men had a higher prob-
ability than women for developing esophageal cancer between
birth and age 79 years, with 1 in 73 men being diagnosed vs 1 in
203 women.
Globally, esophageal cancer ranked ninth for cancer incidence
and sixth for cancer death in 2013 (Figures 3 and 4). In developed
countries, esophageal cancer was only the 20th greatest cause for
cancer incidence but the 11th leading cause for cancer death. In de-
veloping countries, esophageal cancer ranked eighth for cancer in-
cidence and fifth for mortality.
Esophageal cancer ASIRs and ASDRs per 100 000 in 2013 for
both sexes were higher in developing countries vs developed
countries (ASIR, 8.94 vs 3.90; ASDR, 9.11 vs 3.79) (web tables 7
and 8). As detailed in web tables 4 and 5, in 2013 incidence rates
per 100 000 for men were the lowest in Andean Latin America
(ASIR, 2.41; ASDR, 2.49), central Latin America (ASIR, 3.46; ASDR,
3.51), and north Africa and Middle East (ASIR, 3.46; ASDR, 3.74)
and the highest in east Asia (ASIR, 22.04; ASDR, 22.4), southern
sub-Saharan Africa (ASIR, 21.81; ASDR, 22.33), and central Asia
(ASIR, 14.42; ASDR, 14.55). For women, incidence rates per
100 000 in 2013 were the lowest in Andean Latin America (with
ASDRs per 100 000 reported for comparison) (ASIR, 0.64; ASDR,
0.64), eastern Europe (ASIR, 0.88; ASDR, 0.92), and central
Europe (ASIR, 0.99 ASDR, 1.02) and the highest in eastern sub-
Saharan Africa (ASIR, 12.74; ASDR, 13.78), southern sub-Saharan
Africa (ASIR, 8.79; ASDR, 8.55), and south Asia (ASIR, 7.28; ASDR,
7.44) (web tables 1 and 2).
Esophageal cancer was themost commonly diagnosed cancer
in 2013 for men in Malawi and Turkmenistan (eFigure 6a in the
Supplement) and the most common cause of cancer death in Co-
moros, Djibouti, Kenya, Malawi, Somalia, South Sudan, Turkmeni-
stan, andZimbabwe (eFigure6c in the Supplement). Forwomen, it
was themostcommoncauseofcancerdeath in2013 in IranandTurk-
menistan (eFigure 6d in the Supplement).
Figure3showsamarkeddifferencebetweenthe50mostpopu-
lous countries for esophageal cancer incidence rankings in2013. For
example,while this cancer ranked inmost countries among the least
commoncancers for incidence, itwas thesecondmostcommoncan-
cer for both sexes in Kenya, and the fourthmost common cancer in
Iran. The sameholds true for cancer death rates,where esophageal
cancer ranks first inKenyaandNepal, second inEthiopia, Iran, South
Africa, andUganda,butonly 16th in thePhilippines and 17th inPeru.
Figure 13. Trends in Age-Standardized Incidence Rates for Non-Hodgkin Lymphoma, 1990-2013
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Esophagealcancerhas increasedfromtheseventh leadingcause
for cancerYLLs in 1990 to the sixth leading cause in2013 (Figure5).
Aging and growing populations are the drivers behind the increase
in esophageal cancer cases from 304 000 in 1990 to 442 000 in
2013. If thepopulationagestructureandsizehadremainedthesame
in 2013 as in 1990, 29.3% fewer cases of esophageal cancer would
have been diagnosed in 2013 than in 1990 (Table 2). Worldwide
and in developing regions, age-standardized incidence rates ap-
pear to be declining (Figure 14). Between 1990 and 2013, age-
standardizedDALY rates for both sexesdecreasedby23%globally,
by 28% in developing countries, and by 18% in developed coun-
tries (web table 9).
Leukemia
In 2013, therewere414 000newcasesof leukemiaworldwide and
265 000deaths. Leukemia caused9.3millionDALYs globally, with
78%occurring indeveloping countries and22%occurring indevel-
oped countries (web table 9). One in 127 men vs 1 in 203 women
developed leukemia between birth and age 79 years.
Globally, leukemia ranked 10th for cancer incidence and ninth
for cancer deaths in 2013. In developed countries, leukemia ranked
12th for incidenceandeighth for cancerdeaths. Indevelopingcoun-
tries, it ranked10th forcancer incidenceandeighth forcancerdeaths
(Figures 3 and 4).
TheASIRs andASDRsper 100 000 in2013 forboth sexeswere
higher in developed countries vs developing countries (ASIR, 8.15
vs 5.09; ASDR, 4.78 vs 3.46) (web tables 7 and 8). In 2013 inci-
dence rates per 100 000 for both sexes were the lowest in west-
ern sub-SaharanAfrica (withASDRsper 100 000reported for com-
parison) (ASIR, 1.34; ASDR, 1.15), eastern sub-Saharan Africa (ASIR,
1.58;ASDR, 1.47), andcentral sub-SaharanAfrica (ASIR, 2.30;ASDR,
2.03)andhighest inhigh-incomeNorthAmerica (ASIR, 10.67;ASDR,
5.54),Australasia (ASIR,9.97;ASDR,5.13),andWesternEurope(ASIR,
8.24; ASDR, 5.08).
Leukemia was the cancer with themost incident cases in 2013
for men in Iraq (eFigure 6a in the Supplement).
eFigure 4a in the Supplement shows amarked difference in in-
cidence rankingsbetweencountries. Leukemia ranksamongthe top
most common cancers for both sexes in Iraq, Jordan, and Kuwait,
while it ismuch less common inmostother countries. Leukemiahas
decreased fromthe fifth leadingcauseof cancerYLLs in 1990to the
seventh leading cause in2013,with a9%decrease in absoluteYLLs
and a 31% decrease in age-standardized YLLs (Figure 5).
Between 1990 and 2013, incident cases at the global level in-
creased from297 000to414 000,withpopulationgrowthandag-
ing being the drivers behind this increase. Had ASIRs remained the
same in 2013 as in 1990, there would be 8%more cases of leuke-
mia in 2013 (Table 2). For women, trends in ASIRs appear to be de-
creasing globally as well as in developed and developing countries
(Figure 15). Formen,ASIRs increasedup to themid-1990sandhave
decreased since in developing countries, with a stable trend in de-
veloping countries.
Between 1990and2013, age-standardizedDALY rates forboth
sexes decreased by 30% at the global level, by 33% in developed
countries, and by 30% in developing countries (web table 9).
Trends in Incidence for Less Common Cancers
As detailed in web table 7, ASIRs per 100 000 for both sexes in-
creased substantially between 1990 and 2013 for certain cancers.
Kidney cancerASIRs, for example, increased for both sexes by 23%
(from 3.82 to 4.7). Rates in developing countries were lower than
indevelopedcountriesbut the relative increasewas similar: 34% in-
crease in developing countries (from 1.69 to 2.27) and 36% in-
crease in developed countries (from 7.15 to 9.71).
For thyroidcancer,ASIRsper 100 000onaglobal scale forboth
sexes increased by 20% (from2.74 to 3.3), with a larger relative in-
crease in developing countries (33%; from2.06 to2.74) than in de-
veloped countries (19%; from 4.16 to 4.95).
Mesothelioma ASIRs per 100 000 increased by 15% for both
sexes globally (from0.48 to0.55), with a larger relative increase in
developing countries of 26% (from 0.31 to 0.39) compared with a
14% increase in developed countries (from 0.7 to 0.8).
Pancreatic cancer ASIRs per 100 000 have increased globally
for both sexes by 9% (5.31 to 5.78)with a larger relative increase in
developing(29%from2.84to3.66)comparedwithdevelopedcoun-
tries (10% from 8.6 to 9.54).
Forother cancers, rates substantially decreasedbetween 1990
and 2013. Globally, ASIRs per 100 000 for both sexes for gallblad-
Figure 14. Trends in Age-Standardized Incidence Rates for Esophageal Cancer, 1990-2013
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der and biliary tract cancer decreased by 23% (from 3.99 to 3.09),
withasmaller relativedecreaseof 18%indevelopingcountries (from
3.09 to 2.52) compared with a 25% decrease in developed coun-
tries (from 5.1 to 3.81). eFigure 4a in the Supplement shows that
gallbladderandbiliary tract cancer is exceptionally common inChile,
Bolivia, and South Korea, where it ranks sixth and seventh for can-
cer incidentcasesvsmostothercountries,where it ismuch lesscom-
mon. Specific ASIRs per 100 000 confirm this finding: 14.85 in
Bolivia, 11.54 in South Korea, and 16.03 in Chile (web table 7).
Larynx cancer ASIRs per 100 000 for both sexes decreased glob-
ally by 25% (from 3.7 to 2.78), with a smaller decrease of 14% in
developing countries (from3.22 to 2.76) comparedwith a 37%de-
crease in developed countries (4.62 to 2.92).
On a global scale, nasopharynx cancer ASIRs per 100 000
decreased for both sexes by 25% (from 1.64 to 1.23), with a
smaller decrease of 27% in developing countries (from 2.07 to
1.52) compared with a 46%decrease in developed countries (from
0.79 to 0.43).
Hodgkin lymphoma ASIRs per 100 000 for both sexes de-
creased globally by 34% (from 2.02 to 1.33), with a larger 37% de-
crease indevelopingcountries (from1.9 to 1.2) comparedwitha 19%
decrease in developed countries (from 2.31 to 1.87).
Discussion
Descriptive cancer epidemiology has a long tradition and has influ-
enced research and policy alike. Trends in cancer incidence are es-
pecially informative frombothahealth systemsanda scientific per-
spective. They can help with resource allocation planning as a
window into the future, and theycanbehypothesis generatingwith
regard to the driving factors behind changes. The GBD provides a
unique source for data on cancer for 3 reasons: (1) a standardized
statistical framework has been used to analyze both cancer regis-
trydata andcauseofdeathdataby country andover time; (2) in ad-
dition to incidence andmortality, othermetrics such asDALYshave
been used to quantify health loss; and (3) the burden caused by an
individual disease can be placed in the context of other diseases or
injuries, which is sine qua non to inform health policy and resource
allocation decisions.
Theestimatespresented in this study reveal remarkablediffer-
ences in trends between cancers. On a global level between 1990
and2013, incident cases for every cancer increased (increases rang-
ing from 9% for cervical cancer to 217% for prostate cancer) ex-
cept for Hodgkin lymphoma, forwhich incidence has decreased by
10% (from 103 000 to93 000). Since the risk formost cancers in-
creases with age, it is not surprising that aging contributed
between 20% and 43% to the absolute increase in incident cases
between 1990 and 2013 (Table 2). With life expectancy increasing
globally, the future burden of cancer will likely increase, unless in-
cidence rates fall substantially.1 Anexampleof suchdramaticallyde-
creasing incidence rates from the present study is cervical cancer;
incidence rates in thisdiseasedecreasedby59%between 1990and
2013, which led to only a 8.5% increase in incident cases. In con-
trast, the increase in incident cervical cancer caseswouldhavebeen
67% if incidence rates had remained constant. Additional ex-
amples of countervailing trends include cancers more common in
youngeragegroups likeHodgkin lymphoma, leukemia, testicularcan-
cer, and brain and nervous system cancer, where population aging
does not contribute to an increase in incident cases.
Of special concern are the increasing incidence rates in can-
cers that are also more common in older age groups, since this
combination leads to the largest increase in incident cases. Pros-
tate cancer, NHL, thyroid cancer, breast cancer, mesothelioma,
colon and rectum cancer, and pancreatic cancer all fall into this
category. Prostate cancer cases increased by 217% between 1990
and 2013 on a global scale, by 169% in developed countries, and
by 361% in developing countries. Population aging has contrib-
uted a larger proportion to this increase in developing countries vs
developed countries (54% vs 39%) (eTable 16 in the Supplement),
which is not surprising, given the faster rise in life expectancy in
developing countries. However, 265% of the 361% increase in inci-
dence numbers is due to an increase in age-specific incidence
rates. It is unclear how much of the overall increase can be attrib-
uted to ascertainment bias, but it is unlikely that this would fully
explain such a substantial increase in developing countries, given
Figure 15. Trends in Age-Standardized Incidence Rates for Leukemia, 1990-2013
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that screening for prostate cancer is not widely practiced in low-
and middle-income countries.
Between 1990 and 2013, kidney cancer cases for both sexes
increased by 107%, with equal contribution from aging popula-
tions and increasing incidence rates. Incidence rates are still over
4-fold lower in developing countries than in developed countries
but with a surprisingly similar relative increase in ASIRs (34% in
developing countries, 36% in developed countries). This is an
exception to most other cancers for which relative changes in
trends show a marked difference by development status. Many
potential risk factors for kidney cancer have been described in the
literature, including smoking, obesity, hypertension, and occupa-
tional exposures.27-30 One possible explanation for the similar
trend in incidence rates between developing and developed coun-
tries is that even though single risk factors for kidney cancer differ
by development status, the overall risk factor pattern might com-
pensate for this disparity.
Thyroid cancer is another example of a cancer with an alarm-
ing rise in incidence. For both sexes, incident cases almost doubled
between 1990 and 2013 (95% increase). Population growth, ag-
ing, and increasing rates contributed similar proportions to this in-
crease.However,whileASIRs increasedgloballyby20%,ASDRsde-
creased by 19% (web table 8). This finding supports the previously
recognized notion that at least part of the “thyroid cancer epi-
demic” can be attributed to overdiagnosis due to the increased use
of imaging examinations.31-33
In contrast to thegroupof cancerswhere rising incidence rates
contribute substantially to the increase in absolute cases are the
group of cancers with decreasing rates. Population growth and ag-
ingstill result ina largernumberofcases in2013comparedwith1990,
but part of this increase is offset by falling rates. At the global level,
Hodgkin lymphoma and cervical, stomach, larynx, nasopharynx,
gallbladderandbiliary tract, esophageal, andbladder cancer fall into
this group.
Focusing on Cancer Prevention
Obviously the interpretation of trends simplifies substantial differ-
ences between and within regions and countries as well as be-
tweenagegroups. Theestimates are therefore alsoprovidedat the
country level, by age and sex groups. However, the description of
patterns by development status or region can help correctmiscon-
ceptions. Cancer has long been regarded as a problemof economi-
cally developed countries,with the reasoning that cancer burden is
substantially higher in affluent countries and that cancer care re-
quires toomany resources and is too complex to provide in less de-
veloped countries. The lack of focus on cancer and other NCDs is
highlightedby theMillenniumDevelopmentGoals (MDGs),34which
donot includeanyNCDs.However, even though the total 2013ASIR
per 100 000 for cancer was 1.7 times higher in developed regions
vs developing regions (328 vs 190), death rates per 100 000were
only 1.2 times higher (148 vs 123). Between 1990 and 2013, ASIRs
increased inmost countries (Figure2A), includingdeveloping coun-
tries, where the existing health care systems are already over-
whelmedby theburdenof communicablediseases. This rise in can-
cer incidence has been attributed to increased life expectancy and
an increasing prevalence of risk factors like overweight and obe-
sity, smoking,alcoholconsumption,andhypertension.1,35-37Toavoid
an NCD epidemic that could reverse health care advances already
achieved in reducing the burden of communicable disease, cancer
prevention efforts must be a priority.
Tracheal, bronchus, and lung cancer, cervical cancer, and liver
canceraregoodexamples in this aspect.Currently,TBLcancerASIRs
for men in regions with low smoking prevalence like sub-Saharan
Africa (except southern sub-SaharanAfrica) are 5 to 10 times lower
than incountrieswithhistoricallyhighsmokingprevalence likehigh-
income North America, Europe, and east Asia. For women, the dif-
ference is evenmore striking,witha 15-folddifference in2013ASIRs
per 100 000 between western sub-Saharan Africa and high-
income North America (2.76 vs 41.8), and it is critical that public
healtheffortsensurethatsmokingratesremain lowinthefuture.38,39
However, smoking is only 1 risk factor for TBL cancer. East Asian
womenhavethethirdhighestASIR forTBLcancer (23per 100 000),
behind high-incomeNorth America (42 per 100 000) andAustral-
asia (25 per 100 000), even though smoking rates are substan-
tially lower for women in east Asia than they are in other countries
withsimilar incidencerates.38Geneticsusceptibilitymightplayarole,
but preventable risk factors like household air pollution have also
been identified as a reason behind this unusual pattern.40-44
Cervical cancer rates in regions with screening programs, like
Australasia,high-incomeNorth-America,WesternEurope,andhigh-
income Asia Pacific, are below 10 per 100 000, whereas rates are
up to 3 times as high in countries without screening programs (29
per 100 000 inAndeanLatinAmerica, 30per 100 000 inwestern
sub-Saharan Africa, and 58 per 100 000 in Oceania). It is encour-
aging that between 1990 and 2013, cervical cancer ASIRs de-
creased in all regions between 8% and 47% (web table 1). How-
ever, in 2013, cervical cancer, a preventable and treatable cancer,
remains thecancerwith thehighest incidence inwomen in27coun-
tries and the leading cause of cancer death in women in 45 coun-
tries. Efforts to determine themost cost-effective strategies to re-
duce cervical cancer burden through human papillomavirus
vaccination and screening are ongoing and will hopefully lead to a
continued decrease in cervical cancer incidence in the most af-
fected areas of the world.45-50
Liver cancer ranks second for mortality in developing coun-
tries. Treatment for liver cancer is not very effective, with 2013
ASIRs and ASDRs per 100 000 being very similar in both develop-
ing and developed countries (ASIRs, 14.72 and 7.42, respectively;
ASDRs, 15.59 and 7.26, respectively). The main risk factors for liver
cancer are hepatitis B infection, hepatitis C infection, and chronic
hepatitis and cirrhosis due to alcohol and other causes.51-56 In
2013, of the 818 000 deaths in men and women, 300 000 (37%)
were estimated to be due to hepatitis B infection, 343 000 (42%)
due to hepatitis C infection, 92 000 (11%) due to alcohol abuse,
and 83 000 (10%) due to other causes.1 Hepatitis B vaccination
has proven cost-effective in preventing liver cancer due to hepati-
tis B, and treatment for hepatitis C, although expensive, has
recently shown success.57,58
Study Limitations
The core components of the GBD cancer estimates are cancer reg-
istry and vital registry data. However, these sources are sparse in
many low-andmiddle-incomecountries, and in theabsenceofdata,
theestimatesaredependentoncovariateselectionandregionalpat-
terns. This is accounted forbyestimatinguncertainty intervals (pro-
vided for all estimates in eTables in the Supplement). Even though
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cancer registrydataareconsidered thegold standard for cancer sur-
veillance, the quality of registries can vary substantially. Underre-
porting of cancer cases or deaths or a high proportion of undefined
codes can lead tocancer registrydata thatdonot represent the true
cancerburden.59-62Asdescribed in theMethods section, our analy-
sis is thereforeheavily basedoncause-of-deathdata and to a lesser
degree on cancer registry data. This explainswhy the estimates re-
portedmight bedifferent fromcancer registry data. Toensure con-
sistency, robustness, and clarity in this framework, the same esti-
mation methods were used for all cancers, as well as advanced
modeling techniques like ensemblemodels with a large pool of co-
variates andout-of-samplevalidation. Thebenefit of estimating the
different cancers within the GBD framework is that it ensures that
cancerestimatesareadjustedtobeconsistentwiththeall-causemor-
tality estimates, preventing inflation or underestimation of cause-
specific estimates. A detailed description of these methods is pro-
vided in the eAppendix in the Supplement. While quite advanced,
thesemethodologies still result in only estimates, which should be
usedasplaceholdersuntil high-qualitydatabecomeavailable.Hope-
fully, the newly launched Global Initiative for Cancer Registry
Development,63 an effort to expand cancer registries in low- and
middle-incomecountries,will lead to improveddataavailability and
quality in these countries.
Underreportingofnewcancer cases to cancer registriesormis-
coding cause of death can lead to MI ratios that are either too low
or too high.64,65 Miscoding is especially common in countries with
limiteddiagnostic resources andariseswhenmetastatic lesions are
coded as primary cancers, which can lead to overestimation of pri-
mary cancers in anatomic sites where metastases are often found
(eg, liver or brain). Also, increasing incidence rateswith stablemor-
tality rates can lead toanunderestimationofMI ratios, anddecreas-
ing incidence rates with stable mortality rates can lead toMI ratios
higher than 1. These factors can result in seemingly implausible es-
timates likehigher estimates for cancer deaths comparedwith can-
cer incident cases in the same year. Changing classification sys-
tems (eg, from ICD-9 Basic Tabulation List to ICD-9 detail) can also
lead to substantial changes in estimates over time. To improve the
quality of the data sources and to ensure comparability, garbage
codes or undefined cancer codeswere redistributed , anddifferent
coding systems weremapped to a set of uniform GBD causes.
To estimate YLDs,MI ratioswere used as surrogates for cancer
survival owing to lack of high-quality survival data in most coun-
tries. Using MI ratios as a surrogate for survival is problematic be-
cause of the different patient cohorts with changing survival prob-
abilities that are captured in themortalitynumerator. Theapproach
taken in thepresentanalysis, therefore,was touseMI ratios asa sur-
rogate for access to care, which avoids the problem with “back-
scattering”ofdifferentcohorts.66However, survivaldata remain the
gold standard, and availability of survival data has increased with
the recently published CONCORD-2 study,4 which provides sur-
vival estimates for 67 countries.
Conclusions
Cancer was the second leading cause of death in 2013 after cardio-
vascular disease (eFigure 5a in the Supplement), and cancer bur-
den as part of the NCDs is expected to increase in all countries due
to population growth, aging, and an increasing prevalence of cer-
tain risk factors.1 The health community has responded to this
global health threat through endorsing the “25 by 25” strategy as
part of the NCD Global Monitoring Framework during the World
Health Assembly in 2012,67 with the goal of reducing avoidable
mortality from NCDs by 25% by 2025. This is a challenging goal
and will require commitment from all levels of society. Population-
level observations of cancer burden and time trends as presented
herein help highlight aspects of cancer epidemiology that can
guide intervention programs and advance research in cancer
determinants and outcomes.
Cancer control strategies have to be prioritized based on local
needs, and current data on cancer burdenwill be necessary for the
developmentofnationalNCDactionandcancer control plans. In ac-
knowledgment of this need, annual updates of the burden of can-
cer will be published.
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